What is Maravai Lifesciences Holdings, Inc.'s earnings per share (EPS)?

Maravai Lifesciences Holdings, Inc. (MRVI) reported diluted earnings per share of $-0.90 for fiscal year 2025. This represents a 14.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Maravai Lifesciences Holdings, Inc. Financials

MRVI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Maravai Lifesciences Holdings, Inc. (MRVI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 29/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Maravai Lifesciences Holdings, Inc. has an operating margin of -115.9%, meaning the company retains $-116 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -90.9% the prior year.

Growth

Maravai Lifesciences Holdings, Inc.'s revenue declined 28.3% year-over-year, from $259.2M to $185.7M. This contraction results in a growth score of 0/100.

Leverage

Maravai Lifesciences Holdings, Inc. carries a low D/E ratio of 1.35, meaning only $1.35 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 75/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.60, Maravai Lifesciences Holdings, Inc. holds $6.60 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Maravai Lifesciences Holdings, Inc. generated -$57.6M in operating cash flow, capex of $13.1M consumed most of it, leaving -$70.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Maravai Lifesciences Holdings, Inc. generates a -61.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -44.5% the prior year.

Piotroski F-Score Weak

1/9

Maravai Lifesciences Holdings, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality Low Quality

0.44x

For every $1 of reported earnings, Maravai Lifesciences Holdings, Inc. generates $0.44 in operating cash flow (-$57.6M OCF vs -$130.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-8.0x

Maravai Lifesciences Holdings, Inc. earns $-8.0 in operating income for every $1 of interest expense (-$215.3M vs $27.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$185.7M

YoY-28.3%

5Y CAGR-8.1%

Maravai Lifesciences Holdings, Inc. generated $185.7M in revenue in fiscal year 2025. This represents a decrease of 28.3% from the prior year.

EBITDA

-$163.8M

YoY+12.5%

Maravai Lifesciences Holdings, Inc.'s EBITDA was -$163.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 12.5% from the prior year.

Net Income

-$130.8M

YoY+9.7%

Maravai Lifesciences Holdings, Inc. reported -$130.8M in net income in fiscal year 2025. This represents an increase of 9.7% from the prior year.

EPS (Diluted)

$-0.90

YoY+14.3%

Maravai Lifesciences Holdings, Inc. earned $-0.90 per diluted share (EPS) in fiscal year 2025. This represents an increase of 14.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$70.7M

YoY-218.7%

Maravai Lifesciences Holdings, Inc. generated -$70.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 218.7% from the prior year.

Cash & Debt

$216.9M

YoY-32.7%

5Y CAGR-1.7%

Maravai Lifesciences Holdings, Inc. held $216.9M in cash against $286.3M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

18.3%

YoY-23.5pp

5Y CAGR-53.7pp

Maravai Lifesciences Holdings, Inc.'s gross margin was 18.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 23.5 percentage points from the prior year.

Operating Margin

-115.9%

YoY-25.0pp

5Y CAGR-158.1pp

Maravai Lifesciences Holdings, Inc.'s operating margin was -115.9% in fiscal year 2025, reflecting core business profitability. This is down 25.0 percentage points from the prior year.

Net Margin

-70.4%

YoY-14.5pp

5Y CAGR-101.7pp

Maravai Lifesciences Holdings, Inc.'s net profit margin was -70.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 14.5 percentage points from the prior year.

Return on Equity

-61.6%

YoY-17.1pp

5Y CAGR-162.1pp

Maravai Lifesciences Holdings, Inc.'s ROE was -61.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 17.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$17.4M

YoY-9.5%

5Y CAGR+13.3%

Maravai Lifesciences Holdings, Inc. invested $17.4M in research and development in fiscal year 2025. This represents a decrease of 9.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$13.1M

YoY-55.7%

5Y CAGR-12.3%

Maravai Lifesciences Holdings, Inc. invested $13.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 55.7% from the prior year.

MRVI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$185.7M-28.3%	$259.2M-10.3%	$288.9M-67.3%	$883.0M+10.5%	$799.2M+181.3%	$284.1M
Cost of Revenue	$151.8M+0.6%	$150.9M+1.4%	$148.7M-12.0%	$169.0M+20.2%	$140.6M+76.5%	$79.6M
Gross Profit	$34.0M-68.6%	$108.3M-22.7%	$140.2M-80.4%	$714.0M+8.4%	$658.7M+222.2%	$204.4M
R&D Expenses	$17.4M-9.5%	$19.2M+11.2%	$17.3M-5.9%	$18.4M+20.7%	$15.2M+63.6%	$9.3M
SG&A Expenses	$145.1M-10.3%	$161.8M+6.9%	$151.4M+17.1%	$129.3M+29.2%	$100.1M+6.2%	$94.2M
Operating Income	-$215.3M+8.6%	-$235.6M-644.5%	-$31.6M-105.5%	$574.2M+3.5%	$554.6M+362.6%	$119.9M
Interest Expense	$27.0M-43.4%	$47.7M+3.9%	$45.9M+124.8%	$20.4M-32.5%	$30.3M-1.6%	$30.7M
Income Tax	-$4.2M-126.5%	-$1.9M-100.2%	$756.1M+1143.4%	$60.8M-1.1%	$61.5M+2035.9%	$2.9M
Net Income	-$130.8M+9.7%	-$144.8M-21.7%	-$119.0M-154.1%	$220.2M+21.0%	$182.0M+104.6%	$89.0M
EPS (Diluted)	$-0.90+14.3%	$-1.05-16.7%	$-0.90-153.9%	$1.67+7.1%	$1.56-33.9%	$2.36

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$49.9M+19.8%	$41.6M-12.2%	$47.4M+1.2%	$46.9M-17.2%	$56.6M-18.1%	$69.0M-0.6%	$69.4M+8.2%	$64.2M
Cost of Revenue	$37.0M+2.9%	$36.0M-9.2%	$39.6M+1.3%	$39.1M+5.3%	$37.2M+1.0%	$36.8M-4.6%	$38.6M+0.6%	$38.3M
Gross Profit	$12.8M+127.1%	$5.7M-27.2%	$7.8M+0.6%	$7.7M-60.2%	$19.4M-39.8%	$32.2M+4.5%	$30.8M+19.3%	$25.8M
R&D Expenses	$3.8M-1.5%	$3.8M-21.3%	$4.9M-0.1%	$4.9M+7.2%	$4.6M-3.0%	$4.7M-4.5%	$4.9M-2.1%	$5.0M
SG&A Expenses	$31.6M-10.8%	$35.4M-8.2%	$38.6M-2.5%	$39.6M-4.1%	$41.2M+5.5%	$39.1M-3.6%	$40.6M-0.8%	$40.9M
Operating Income	-$58.8M-43.3%	-$41.0M+38.1%	-$66.3M-34.8%	-$49.2M-30.4%	-$37.7M+77.2%	-$165.6M-1132.2%	-$13.4M+28.7%	-$18.9M
Interest Expense	$6.6M-4.2%	$6.8M+0.4%	$6.8M+0.5%	$6.8M-39.8%	$11.3M-17.4%	$13.6M+14.2%	$11.9M+9.9%	$10.9M
Income Tax	$6K+106.5%	-$92K+97.9%	-$4.3M-2746.9%	$162K+2414.3%	-$7K-102.3%	$311K+112.8%	-$2.4M-998.5%	$271K
Net Income	-$35.7M-39.6%	-$25.6M+35.4%	-$39.6M-32.2%	-$29.9M-15.6%	-$25.9M+73.3%	-$97.1M-891.7%	-$9.8M+19.0%	-$12.1M
EPS (Diluted)	N/A	$-0.18+33.3%	$-0.27-28.6%	$-0.21	N/A	$-0.68-871.4%	$-0.07+22.2%	$-0.09

MRVI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$770.6M-23.6%	$1.0B-32.2%	$1.5B-34.8%	$2.3B+19.0%	$1.9B+51.0%	$1.3B
Current Assets	$296.3M-31.0%	$429.1M-38.7%	$699.9M-17.5%	$847.9M+14.6%	$740.0M+123.2%	$331.6M
Cash & Equivalents	$216.9M-32.7%	$322.4M-43.9%	$575.0M-9.0%	$632.1M+14.7%	$551.3M+133.4%	$236.2M
Inventory	$40.5M-19.1%	$50.1M-2.6%	$51.4M+19.1%	$43.2M-16.3%	$51.6M+54.8%	$33.3M
Accounts Receivable	$25.5M-33.8%	$38.5M-29.5%	$54.6M-60.6%	$138.6M+18.0%	$117.5M+130.3%	$51.0M
Goodwill	$129.4M-19.0%	$159.9M-51.0%	$326.0M+14.9%	$283.7M+85.7%	$152.8M-31.9%	$224.3M
Total Liabilities	$558.2M-18.3%	$683.0M-36.2%	$1.1B-22.2%	$1.4B+0.3%	$1.4B+23.0%	$1.1B
Current Liabilities	$44.9M-21.2%	$57.0M-34.9%	$87.5M-20.6%	$110.1M+17.5%	$93.8M-28.3%	$130.8M
Long-Term Debt	$286.3M-1.4%	$290.5M-44.0%	$518.7M-0.6%	$522.0M-0.5%	$524.6M-0.8%	$528.6M
Total Equity	$212.4M-34.7%	$325.3M-21.9%	$416.8M-23.6%	$545.2M+72.8%	$315.5M+256.5%	$88.5M
Retained Earnings	$10.1M-92.8%	$140.9M-50.7%	$285.7M-29.4%	$404.8M+119.3%	$184.6M+21511.4%	$854K

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$770.6M-9.3%	$849.2M-5.3%	$897.0M-6.5%	$959.8M-4.8%	$1.0B-21.1%	$1.3B-11.5%	$1.4B-0.1%	$1.4B
Current Assets	$296.3M-9.1%	$325.9M-9.4%	$359.8M-4.4%	$376.3M-12.3%	$429.1M-36.8%	$679.1M-0.3%	$681.5M+2.0%	$667.9M
Cash & Equivalents	$216.9M-11.0%	$243.6M-9.8%	$269.9M-5.3%	$285.1M-11.6%	$322.4M-44.2%	$578.2M+0.9%	$573.2M+2.0%	$561.7M
Inventory	$40.5M-10.7%	$45.3M-2.9%	$46.7M-6.2%	$49.8M-0.6%	$50.1M-0.9%	$50.5M+2.4%	$49.3M-1.0%	$49.8M
Accounts Receivable	$25.5M+13.1%	$22.5M-19.2%	$27.9M-2.1%	$28.5M-26.0%	$38.5M+33.8%	$28.8M-17.1%	$34.7M-5.3%	$36.7M
Goodwill	$129.4M0.0%	$129.4M0.0%	$129.4M-19.0%	$159.9M0.0%	$159.9M-6.9%	$171.8M-47.3%	$326.0M0.0%	$326.0M
Total Liabilities	$558.2M-7.5%	$603.7M-4.3%	$631.1M-4.3%	$659.1M-3.5%	$683.0M-26.8%	$933.4M-7.5%	$1.0B-2.4%	$1.0B
Current Liabilities	$44.9M-27.1%	$61.6M-11.6%	$69.7M+10.3%	$63.2M+10.9%	$57.0M-10.6%	$63.7M-7.2%	$68.6M+16.3%	$59.0M
Long-Term Debt	$286.3M-0.4%	$287.4M-0.4%	$288.4M-0.4%	$289.5M-0.3%	$290.5M-43.7%	$516.3M-0.2%	$517.1M-0.2%	$517.9M
Total Equity	$212.4M-13.5%	$245.4M-7.7%	$265.9M-11.6%	$300.6M-7.6%	$325.3M-5.7%	$344.9M-20.7%	$434.7M+5.9%	$410.7M
Retained Earnings	$10.1M-77.9%	$45.8M-35.8%	$71.4M-35.7%	$110.9M-21.3%	$140.9M-15.5%	$166.8M-36.8%	$263.9M-3.6%	$273.7M

MRVI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$57.6M-871.2%	$7.5M-94.1%	$126.2M-76.4%	$536.0M+45.4%	$368.6M+142.2%	$152.2M
Capital Expenditures	$13.1M-55.7%	$29.7M-54.8%	$65.6M+283.6%	$17.1M+15.1%	$14.8M-41.6%	$25.4M
Free Cash Flow	-$70.7M-218.7%	-$22.2M-136.6%	$60.7M-88.3%	$518.9M+46.7%	$353.7M+179.0%	$126.8M
Investing Cash Flow	-$31.4M-29.2%	-$24.3M+80.1%	-$122.3M+54.3%	-$267.6M-353.3%	$105.7M+1641.2%	$6.1M
Financing Cash Flow	-$16.5M+93.0%	-$235.7M-285.8%	-$61.1M+67.4%	-$187.5M-17.9%	-$159.0M-398.9%	$53.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	$0-100.0%	$33.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$22.8M-50.3%	-$15.2M-47.6%	-$10.3M-9.3%	-$9.4M+35.9%	-$14.6M-211.4%	$13.1M-24.7%	$17.4M+305.9%	-$8.5M
Capital Expenditures	$2.1M-27.8%	$2.9M+1.8%	$2.9M-45.1%	$5.2M-10.5%	$5.8M-31.9%	$8.6M-10.1%	$9.6M+68.6%	$5.7M
Free Cash Flow	-$24.9M-37.7%	-$18.1M-37.6%	-$13.1M+10.2%	-$14.6M+28.6%	-$20.5M-550.8%	$4.5M-42.3%	$7.9M+155.8%	-$14.1M
Investing Cash Flow	-$2.1M+27.8%	-$2.9M+9.6%	-$3.2M+86.0%	-$23.1M-369.1%	-$4.9M+45.0%	-$9.0M-44.9%	-$6.2M-45.7%	-$4.2M
Financing Cash Flow	-$1.8M+78.0%	-$8.2M-437.7%	-$1.5M+68.7%	-$4.9M+97.9%	-$236.2M-29295.2%	$809K+254.8%	$228K+140.7%	-$560K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

MRVI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	18.3%-23.5pp	41.8%-6.7pp	48.5%-32.3pp	80.9%-1.5pp	82.4%+10.5pp	72.0%
Operating Margin	-115.9%-25.0pp	-90.9%-80.0pp	-10.9%-76.0pp	65.0%-4.4pp	69.4%+27.2pp	42.2%
Net Margin	-70.4%-14.5pp	-55.9%-14.7pp	-41.2%-66.1pp	24.9%+2.2pp	22.8%-8.5pp	31.3%
Return on Equity	-61.6%-17.1pp	-44.5%-16.0pp	-28.6%-69.0pp	40.4%-17.3pp	57.7%-42.8pp	100.5%
Return on Assets	-17.0%-2.6pp	-14.4%-6.4pp	-8.0%-17.6pp	9.7%+0.2pp	9.5%+2.5pp	7.0%
Current Ratio	6.60-0.9	7.53-0.5	8.00+0.3	7.70-0.2	7.89+5.4	2.54
Debt-to-Equity	1.35+0.5	0.89-0.4	1.24+0.3	0.96-0.7	1.66-4.3	5.97
FCF Margin	-38.1%-29.5pp	-8.6%-29.6pp	21.0%-37.8pp	58.8%+14.5pp	44.3%-0.4pp	44.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	25.8%+12.2pp	13.6%-2.8pp	16.4%-0.1pp	16.5%-17.8pp	34.3%-12.4pp	46.7%+2.3pp	44.4%+4.1pp	40.3%
Operating Margin	-117.9%-19.4pp	-98.6%+41.3pp	-139.8%-34.9pp	-104.9%-38.3pp	-66.7%+173.3pp	-239.9%-220.6pp	-19.4%+10.0pp	-29.4%
Net Margin	-71.5%-10.2pp	-61.4%+22.1pp	-83.5%-19.6pp	-63.9%-18.1pp	-45.8%+94.8pp	-140.6%-126.5pp	-14.1%+4.7pp	-18.8%
Return on Equity	-16.8%-6.4pp	-10.4%+4.5pp	-14.9%-4.9pp	-10.0%-2.0pp	-8.0%+20.2pp	-28.1%-25.9pp	-2.3%+0.7pp	-2.9%
Return on Assets	-4.6%-1.6pp	-3.0%+1.4pp	-4.4%-1.3pp	-3.1%-0.5pp	-2.6%+5.0pp	-7.6%-6.9pp	-0.7%+0.2pp	-0.8%
Current Ratio	6.60+1.3	5.29+0.1	5.16-0.8	5.96-1.6	7.53-3.1	10.66+0.7	9.93-1.4	11.32
Debt-to-Equity	1.35+0.2	1.17+0.1	1.08+0.1	0.96+0.1	0.89-0.6	1.50+0.3	1.19-0.1	1.26
FCF Margin	-49.9%-6.5pp	-43.4%-15.7pp	-27.7%+3.5pp	-31.2%+5.0pp	-36.2%-42.8pp	6.6%-4.8pp	11.3%+33.4pp	-22.0%

Similar Companies

Mimedx Group Inc MDXG

$576.4M

Cormedix CRMD

$559.7M

180 Life Sciences Corp ATNF

$1.1B

Oric Pharmaceuticals, Inc. ORIC

$998.0M

Verve Therapeutics, Inc. VERV

$994.0M

Frequently Asked Questions

What is Maravai Lifesciences Holdings, Inc.'s annual revenue?

Maravai Lifesciences Holdings, Inc. (MRVI) reported $185.7M in total revenue for fiscal year 2025. This represents a -28.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Maravai Lifesciences Holdings, Inc.'s revenue growing?

Maravai Lifesciences Holdings, Inc. (MRVI) revenue declined by 28.3% year-over-year, from $259.2M to $185.7M in fiscal year 2025.

Is Maravai Lifesciences Holdings, Inc. profitable?

No, Maravai Lifesciences Holdings, Inc. (MRVI) reported a net income of -$130.8M in fiscal year 2025, with a net profit margin of -70.4%.

What is Maravai Lifesciences Holdings, Inc.'s EBITDA?

Maravai Lifesciences Holdings, Inc. (MRVI) had EBITDA of -$163.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Maravai Lifesciences Holdings, Inc. have?

As of fiscal year 2025, Maravai Lifesciences Holdings, Inc. (MRVI) had $216.9M in cash and equivalents against $286.3M in long-term debt.

What is Maravai Lifesciences Holdings, Inc.'s gross margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had a gross margin of 18.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Maravai Lifesciences Holdings, Inc.'s operating margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had an operating margin of -115.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Maravai Lifesciences Holdings, Inc.'s net profit margin?

Maravai Lifesciences Holdings, Inc. (MRVI) had a net profit margin of -70.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Maravai Lifesciences Holdings, Inc.'s return on equity (ROE)?

Maravai Lifesciences Holdings, Inc. (MRVI) has a return on equity of -61.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Maravai Lifesciences Holdings, Inc.'s free cash flow?

Maravai Lifesciences Holdings, Inc. (MRVI) generated -$70.7M in free cash flow during fiscal year 2025. This represents a -218.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Maravai Lifesciences Holdings, Inc.'s operating cash flow?

Maravai Lifesciences Holdings, Inc. (MRVI) generated -$57.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Maravai Lifesciences Holdings, Inc.'s total assets?

Maravai Lifesciences Holdings, Inc. (MRVI) had $770.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Maravai Lifesciences Holdings, Inc.'s capital expenditures?

Maravai Lifesciences Holdings, Inc. (MRVI) invested $13.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Maravai Lifesciences Holdings, Inc. spend on research and development?

Maravai Lifesciences Holdings, Inc. (MRVI) invested $17.4M in research and development during fiscal year 2025.

What is Maravai Lifesciences Holdings, Inc.'s current ratio?

Maravai Lifesciences Holdings, Inc. (MRVI) had a current ratio of 6.60 as of fiscal year 2025, which is generally considered healthy.

What is Maravai Lifesciences Holdings, Inc.'s debt-to-equity ratio?

Maravai Lifesciences Holdings, Inc. (MRVI) had a debt-to-equity ratio of 1.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Maravai Lifesciences Holdings, Inc.'s return on assets (ROA)?

Maravai Lifesciences Holdings, Inc. (MRVI) had a return on assets of -17.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Maravai Lifesciences Holdings, Inc.'s cash runway?

Based on fiscal year 2025 data, Maravai Lifesciences Holdings, Inc. (MRVI) had $216.9M in cash against an annual operating cash burn of $57.6M. This gives an estimated cash runway of approximately 45 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Maravai Lifesciences Holdings, Inc.'s Piotroski F-Score?

Maravai Lifesciences Holdings, Inc. (MRVI) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Maravai Lifesciences Holdings, Inc.'s earnings high quality?

Maravai Lifesciences Holdings, Inc. (MRVI) has an earnings quality ratio of 0.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Maravai Lifesciences Holdings, Inc. cover its interest payments?

Maravai Lifesciences Holdings, Inc. (MRVI) has an interest coverage ratio of -8.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Maravai Lifesciences Holdings, Inc.?

Maravai Lifesciences Holdings, Inc. (MRVI) scores 29 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.